Top

Published in:

01-12-2011 | Review

Mechanisms of tissue injury in lupus nephritis

Authors: Tamara K Nowling, Gary S Gilkeson

Published in: Arthritis Research & Therapy | Issue 6/2011

Abstract

Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage. Nephritis, a major cause of morbidity and mortality in patients with lupus, occurs in approximately 50% of lupus patients. In the present review, we provide an overview of the current research and knowledge concerning mechanisms of renal injury in both lupus-prone mouse models and human lupus patients.

Available only for authorised users

Austin HA, Boumpas DT, Vaughan EM, Balow JE: High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995, 10: 1620-1628.PubMed

Markowitz GS, D'Agati VD: The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007, 71: 491-495. 10.1038/sj.ki.5002118.PubMed

Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, Qu Z, Chen MH, Gao JJ, Li ZY, Zheng X, Ao J, Zhu SN, Wang SX, Zhao MH, Zou WZ, Liu G: Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int. 2010, 77: 820-829. 10.1038/ki.2010.13.PubMed

Ma Q, Battelli L, Hubbs AF: Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol. 2006, 168: 1960-1974. 10.2353/ajpath.2006.051113.PubMedCentralPubMed

Davidson A, Diamond B: Activated basophils give lupus a booster shot. Nat Med. 2010, 16: 635-636. 10.1038/nm0610-635.PubMedCentralPubMed

Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003, 349: 1526-1533. 10.1056/NEJMoa021933.PubMed

Fenton KA, Rekvig OP: A central role of nucleosomes in lupus nephritis. Ann N Y Acad Sci. 2007, 1108: 104-113. 10.1196/annals.1422.012.PubMed

Zykova SN, Seredkina NE, Rekvig OP: Glomerular targets for autoantibodies in lupus nephritis - an apoptotic origin. Ann N Y Acad Sci. 2007, 1108: 1-10. 10.1196/annals.1422.001.PubMed

Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR: Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest. 2004, 114: 679-688.PubMedCentralPubMed

10.

Sinico RA, Rimoldi L, Radice A, Bianchi L, Gallelli B, Moroni G: Anti-C1q autoantibodies in lupus nephritis. Ann N Y Acad Sci. 2009, 1173: 47-51. 10.1111/j.1749-6632.2009.04746.x.PubMed

11.

Lefkowith JB, Gilkeson GS: Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum. 1996, 39: 894-903. 10.1002/art.1780390605.PubMed

12.

Alexander JJ, Hack BK, Jacob A, Chang A, Haas M, Finberg RW, Quigg RJ: Abnormal immune complex processing and spontaneous glomerulonephritis in complement factor H-deficient mice with human complement receptor 1 on erythrocytes. J Immunol. 2010, 185: 3759-3767. 10.4049/jimmunol.1000683.PubMed

13.

Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig OP: Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol. 2006, 168: 1779-1792. 10.2353/ajpath.2006.051329.PubMedCentralPubMed

14.

Mjelle JE, Rekvig OP, Van Der Vlag J, Fenton KA: Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity. 2011, 44: 373-383. 10.3109/08916934.2010.541170.PubMed

15.

Fenton KA, Tommeras B, Marion TN, Rekvig OP: Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity. 2010, 43: 179-188. 10.3109/08916930903305633.PubMed

16.

Fenton K, Fismen S, Hedberg A, Seredkina N, Fenton C, Mortensen ES, Rekvig OP: Anti-dsDNA antibodies promote initiation, and acquired loss of renal Dnase1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. PLoS One. 2009, 4: e8474-10.1371/journal.pone.0008474.PubMedCentralPubMed

17.

Boackle SA, Holers VM: Role of complement in the development of autoimmunity. Curr Dir Autoimmun. 2003, 6: 154-168.PubMed

18.

Truedsson L, Bengtsson AA, Sturfelt G: Complement deficiencies and systemic lupus erythematosus. Autoimmunity. 2007, 40: 560-566. 10.1080/08916930701510673.PubMed

19.

Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS: Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000, 164: 786-794.PubMed

20.

Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS: Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2004, 65: 129-138. 10.1111/j.1523-1755.2004.00371.x.PubMed

21.

Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S: The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum. 2011, 63: 1076-1085. 10.1002/art.30222.PubMedCentralPubMed

22.

Sekine H, Ruiz P, Gilkeson GS, Tomlinson S: The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Molecular Immunol. 2011, 49: 317-323. 10.1016/j.molimm.2011.09.015.

23.

Bao L, Haas M, Quigg RJ: Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2011, 22: 285-295. 10.1681/ASN.2010060647.PubMedCentralPubMed

24.

Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS: Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol. 2001, 166: 6444-6451.PubMed

25.

Wenderfer SE, Wang H, Ke B, Wetsel RA, Braun MC: C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse. Mol Immunol. 2009, 46: 1397-1404. 10.1016/j.molimm.2008.12.004.PubMedCentralPubMed

26.

Wenderfer SE, Ke B, Hollmann TJ, Wetsel RA, Lan HY, Braun MC: C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J Am Soc Nephrol. 2005, 16: 3572-3582. 10.1681/ASN.2005040373.PubMed

27.

Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ: C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol. 2005, 35: 2496-2506. 10.1002/eji.200526327.PubMed

28.

Lenderink AM, Liegel K, Ljubanovic D, Coleman KE, Gilkeson GS, Holers VM, Thurman JM: The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol. 2007, 293: F555-F564. 10.1152/ajprenal.00403.2006.PubMed

29.

Niederer HA, Clatworthy MR, Willcocks LC, Smith KG: FcγRIIB, FcγRIIIB, and systemic lupus erythematosus. Ann N Y Acad Sci. 2010, 1183: 69-88. 10.1111/j.1749-6632.2009.05132.x.PubMed

30.

Grossman JM, Tsao BP: Genetics and systemic lupus erythematosus. Curr Rheumatol Rep. 2000, 2: 13-18. 10.1007/s11926-996-0063-x.PubMed

31.

Zhou XJ, Lv JC, Bu DF, Yu L, Yang YR, Zhao J, Cui Z, Yang R, Zhao MH, Zhang H: Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. Int Immunol. 2010, 22: 45-51. 10.1093/intimm/dxp113.PubMed

32.

Tarzi RM, Cook HT: Role of Fcγ receptors in glomerulonephritis. Nephron Exp Nephrol. 2003, 95: e7-e12. 10.1159/000073018.PubMed

33.

Gergely P, Isaak A, Szekeres Z, Prechl J, Erdei A, Nagy ZB, Gergely J, Poor G: Altered expression of Fcγ and complement receptors on B cells in systemic lupus erythematosus. Ann N Y Acad Sci. 2007, 1108: 183-192. 10.1196/annals.1422.020.PubMed

34.

Fukuyama H, Nimmerjahn F, Ravetch JV: The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol. 2005, 6: 99-106.PubMed

35.

Clynes R, Calvani N, Croker BP, Richards HB: Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors. Clin Exp Immunol. 2005, 141: 230-237. 10.1111/j.1365-2249.2005.02847.x.PubMedCentralPubMed

36.

Lee PY, Kumagai Y, Li Y, Takeuchi O, Yoshida H, Weinstein J, Kellner ES, Nacionales D, Barker T, Kelly-Scumpia K, van Rooijen N, Kumar H, Kawai T, Satoh M, Akira S, Reeves WH: TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupus. J Exp Med. 2008, 205: 2995-3006. 10.1084/jem.20080462.PubMedCentralPubMed

37.

Rahman AH, Eisenberg RA: The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol. 2006, 28: 131-143. 10.1007/s00281-006-0034-3.PubMed

38.

Sun S, Rao NL, Venable J, Thurmond R, Karlsson L: TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007, 6: 223-235. 10.2174/187152807783334300.PubMed

39.

Hase K, Tani K, Shimizu T, Ohmoto Y, Matsushima K, Sone S: Increased CCR4 expression in active systemic lupus erythematosus. J Leukoc Biol. 2001, 70: 749-755.PubMed

40.

Yamada M, Yagita H, Inoue H, Takanashi T, Matsuda H, Munechika E, Kanamaru Y, Shirato I, Tomino Y, Matushima K, Okumura K, Hashimoto H: Selective accumulation of CCR4⁺ T lymphocytes into renal tissue of patients with lupus nephritis. Arthritis Rheum. 2002, 46: 735-740. 10.1002/art.10112.PubMed

41.

Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, Tung K, Tsokos GC: Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol. 2007, 178: 1938-1947.PubMed

42.

Wang Y, Ito S, Chino Y, Goto D, Matsumoto I, Murata H, Tsutsumi A, Hayashi T, Uchida K, Usui J, Yamagata K, Sumida T: Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol. 2010, 159: 1-10. 10.1111/j.1365-2249.2009.04031.x.PubMedCentralPubMed

43.

Wang Y, Ito S, Chino Y, Iwanami K, Yasukochi T, Goto D, Matsumoto I, Hayashi T, Uchida K, Sumida T: Use of laser microdissection in the analysis of renalinfiltrating T cells in MRL/lpr mice. Mod Rheumatol. 2008, 18: 385-393. 10.1007/s10165-008-0074-8.PubMed

44.

Crispin JC, Keenan BT, Finnell MD, Bermas BL, Schur P, Massarotti E, Karlson EW, Fitzgerald LM, Ergin S, Kyttaris VC, Tsokos GC, Costenbader KH: Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum. 2010, 62: 1431-1437.PubMedCentralPubMed

45.

Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC: Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008, 181: 8761-8766.PubMedCentralPubMed

46.

Apostolidis SA, Crispin JC, Tsokos GC: IL-17-producing T cells in lupus nephritis. Lupus. 2011, 20: 120-124. 10.1177/0961203310389100.PubMed

47.

Schiffer L, Sinha J, Wang X, Huang W, von Gersdorff G, Schiffer M, Madaio MP, Davidson A: Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol. 2003, 171: 489-497.PubMed

48.

Wofsy D, Ledbetter JA, Hendler PL, Seaman WE: Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol. 1985, 134: 852-857.PubMed

49.

Cassese G, Lindenau S, de Boer B, Arce S, Hauser A, Riemekasten G, Berek C, Hiepe F, Krenn V, Radbruch A, Manz RA: Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol. 2001, 31: 2726-2732. 10.1002/1521-4141(200109)31:9<2726::AID-IMMU2726>3.0.CO;2-H.PubMed

50.

Sekine H, Watanabe H, Gilkeson GS: Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Fas(lpr) mice. J Immunol. 2004, 172: 3913-3921.PubMed

51.

Espeli M, Bokers S, Giannico G, Dickinson HA, Bardsley V, Fogo AB, Smith KG: Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol. 2011, 22: 296-305. 10.1681/ASN.2010050515.PubMedCentralPubMed

52.

Hutloff A, Buchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A, Dorner T, Kroczek RA: Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. 2004, 50: 3211-3220. 10.1002/art.20519.PubMed

53.

Steinmetz OM, Velden J, Kneissler U, Marx M, Klein A, Helmchen U, Stahl RA, Panzer U: Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int. 2008, 74: 448-457. 10.1038/ki.2008.191.PubMed

54.

Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, Kaverina N, Utset TO, Meehan SM, Quigg RJ, Meffre E, Clark MR: In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol. 2011, 186: 1849-1860. 10.4049/jimmunol.1001983.PubMedCentralPubMed

55.

Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A: Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010, 62: 1457-1468.PubMedCentralPubMed

56.

Shlomchik MJ, Madaio MP, Ni D, Trounstein M, Huszar D: The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med. 1994, 180: 1295-1306. 10.1084/jem.180.4.1295.PubMed

57.

Chan OT, Madaio MP, Shlomchik MJ: B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol. 1999, 163: 3592-3596.PubMed

58.

Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S, Goldman BI, Kehry M, Anolik JH: Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010, 62: 2443-2457. 10.1002/art.27515.PubMedCentralPubMed

59.

Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, Moutsopoulos HM: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005, 52: 501-513. 10.1002/art.20858.PubMed

60.

Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999, 189: 1639-1648. 10.1084/jem.189.10.1639.PubMedCentralPubMed

61.

Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A: Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010, 107: 9813-9818. 10.1073/pnas.0909927107.PubMedCentralPubMed

62.

Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ: Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011, 187: 538-552. 10.4049/jimmunol.1100450.PubMedCentralPubMed

63.

Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V: Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011, 3: 73ra20-10.1126/scitranslmed.3001201.PubMedCentralPubMed

64.

Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M: Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011, 3: 73ra19-10.1126/scitranslmed.3001180.PubMedCentralPubMed

65.

Iwata Y, Furuichi K, Sakai N, Yamauchi H, Shinozaki Y, Zhou H, Kurokawa Y, Toyama T, Kitajima S, Okumura T, Yamada S, Maruyama I, Matsushima K, Kaneko S, Wada T: Dendritic cells contribute to autoimmune kidney injury in MRL-Faslpr mice. J Rheumatol. 2009, 36: 306-314. 10.3899/jrheum.080318.PubMed

66.

Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F: Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008, 58: 251-262. 10.1002/art.23186.PubMed

67.

Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A: Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol. 2008, 180: 1938-1947.PubMedCentralPubMed

68.

Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB: Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci USA. 2010, 107: 3012-3017. 10.1073/pnas.0914902107.PubMedCentralPubMed

69.

Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, Bottinger EP, Ivashkiv L, Kretzler M, Davidson A: A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol. 2011, 186: 4994-5003. 10.4049/jimmunol.1003010.PubMedCentralPubMed

70.

Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP, Bariety J: Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 2001, 59: 304-316.PubMed

71.

Katsiari CG, Liossis SN, Sfikakis PP: The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum. 2010, 39: 491-503. 10.1016/j.semarthrit.2008.11.002.PubMed

72.

Fan X, Oertli B, Wuthrich RP: Up-regulation of tubular epithelial interleukin-12 in autoimmune MRL-Fas(lpr) mice with renal injury. Kidney Int. 1997, 51: 79-86. 10.1038/ki.1997.10.PubMed

73.

Fan X, Wuthrich RP: Upregulation of lymphoid and renal interferon-gamma mRNA in autoimmune MRL-Fas(lpr) mice with lupus nephritis. Inflammation. 1997, 21: 105-112. 10.1023/A:1027399027170.PubMed

74.

Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, Szeto CC: Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. Rheumatology (Oxford). 2006, 45: 951-957. 10.1093/rheumatology/kel029.

75.

Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Lai KB, Li PK, Szeto CC: Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis. 2007, 66: 886-892. 10.1136/ard.2006.063123.PubMedCentralPubMed

76.

Menke J, Bork T, Kutska B, Byrne KT, Blanfeld M, Relle M, Kelley VR, Schwarting A: Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int. 2011, 79: 452-463. 10.1038/ki.2010.438.PubMedCentralPubMed

77.

Schwarting A, Tesch G, Kinoshita K, Maron R, Weiner HL, Kelley VR: IL-12 drives IFN-gamma-dependent autoimmune kidney disease in MRLFas(lpr) mice. J Immunol. 1999, 163: 6884-6891.PubMed

78.

Kikawada E, Lenda DM, Kelley VR: IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology. J Immunol. 2003, 170: 3915-3925.PubMed

79.

Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F: Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol. 2008, 154: 247-254. 10.1111/j.1365-2249.2008.03758.x.PubMedCentralPubMed

80.

Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR: IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol. 1998, 161: 494-503.PubMed

81.

Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schlondorff D: Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001, 12: 1369-1382.PubMed

82.

Eriksson C, Eneslatt K, Ivanoff J, Rantapaa-Dahlqvist S, Sundqvist KG: Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus. 2003, 12: 766-774. 10.1191/0961203303lu467oa.PubMed

83.

Narumi S, Takeuchi T, Kobayashi Y, Konishi K: Serum levels of IFN-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000, 12: 1561-1565. 10.1006/cyto.2000.0757.PubMed

84.

Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR: Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med. 1999, 190: 1813-1824. 10.1084/jem.190.12.1813.PubMedCentralPubMed

85.

Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M: Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford). 2004, 43: 1121-1128. 10.1093/rheumatology/keh277.

86.

Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S, Anders HJ: Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol. 2007, 18: 2350-2358. 10.1681/ASN.2006121348.PubMed

87.

Kiani AN, Johnson K, Chen C, Diehl E, Hu H, Vasudevan G, Singh S, Magder LS, Knechtle SJ, Petri M: Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis. J Rheumatol. 2009, 36: 2224-2230. 10.3899/jrheum.081112.PubMed

88.

Marks SD, Shah V, Pilkington C, Tullus K: Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol (Berlin). 2010, 25: 2283-2288. 10.1007/s00467-010-1605-z.

89.

Dong J, Wang QX, Zhou CY, Ma XF, Zhang YC: Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus. 2007, 16: 101-109. 10.1177/0961203306075383.PubMed

90.

Martinez-Lostao L, Ordi-Ros J, Balada E, Segarra-Medrano A, Majo-Masferrer J, Labrador-Horrillo M, Vilardell-Tarres M: Activation of the signal transducer and activator of transcription-1 in diffuse proliferative lupus nephritis. Lupus. 2007, 16: 483-488. 10.1177/0961203307079618.PubMed

91.

Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA: Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 2008, 4: e1000084-10.1371/journal.pgen.1000084.PubMedCentralPubMed

92.

Singh RR, Saxena V, Zang S, Li L, Finkelman FD, Witte DP, Jacob CO: Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol. 2003, 170: 4818-4825.PubMedCentralPubMed

93.

Jacob CO, Zang S, Li L, Ciobanu V, Quismorio F, Mizutani A, Satoh M, Koss M: Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol. 2003, 171: 1564-1571.PubMed

94.

Weinberg JB, Granger DL, Pisetsky DS, Seldin MF, Misukonis MA, Mason SN, Pippen AM, Ruiz P, Wood ER, Gilkeson GS: The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered N^G-monomethyl-l-arginine. J Exp Med. 1994, 179: 651-660. 10.1084/jem.179.2.651.PubMed

95.

Weinberg JB, Gilkeson GS, Mason RP, Chamulitrat W: Nitrosylation of blood hemoglobin and renal nonheme proteins in autoimmune MRL-lpr/lpr mice. Free Radic Biol Med. 1998, 24: 191-196. 10.1016/S0891-5849(97)00217-7.PubMed

96.

Reilly CM, Olgun S, Goodwin D, Gogal RM, Santo A, Romesburg JW, Ahmed SA, Gilkeson GS: Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. Eur J Immunol. 2006, 36: 1296-1308. 10.1002/eji.200535245.PubMed

97.

Oates JC, Ruiz P, Alexander A, Pippen AM, Gilkeson GS: Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol. 1997, 83: 86-92. 10.1006/clin.1997.4332.PubMedCentralPubMed

98.

Keng T, Privalle CT, Gilkeson GS, Weinberg JB: Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice. Mol Med. 2000, 6: 779-792.PubMedCentralPubMed

99.

Oates JC, Gilkeson GS: The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol. 2006, 121: 243-250. 10.1016/j.clim.2006.06.001.PubMedCentralPubMed

100.

Prasad R, Giri S, Nath N, Singh I, Singh AK: GSNO attenuates EAE disease by S-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia. 2007, 55: 65-77. 10.1002/glia.20436.PubMed

101.

Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS: Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Phys. 1999, 111: 611-621. 10.1046/j.1525-1381.1999.99110.x.PubMed

102.

Oates JC, Shaftman SR, Self SE, Gilkeson GS: Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 2008, 58: 263-272. 10.1002/art.23153.PubMedCentralPubMed

103.

Wang JS, Tseng HH, Shih DF, Jou HS, Ger LP: Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron. 1997, 77: 404-411. 10.1159/000190316.PubMed

104.

Oates JC, Farrelly LW, Hofbauer AF, Wang W, Gilkeson GS: Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. Arthritis Rheum. 2007, 56: 3738-3747. 10.1002/art.22955.PubMedCentralPubMed

105.

Bouali H, Nietert P, Nowling TM, Pandey J, Dooley MA, Cooper G, Harley J, Kamen DL, Oates J, Gilkeson G: Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. J Rheumatol. 2007, 34: 2028-2034.PubMedCentralPubMed

106.

Oates JC, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, Hill BS, Weinberg JB, Cooper GS, Gilkeson GS: Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. J Rheumatol. 2003, 30: 60-67.PubMed

107.

Douglas G, Reilly C, Dooley MA, Page G, Cooper G, Gilkeson G: Angiotensin-converting enzyme (insertion/deletion) and endothelial nitric oxide synthase polymorphisms in patients with systemic lupus erythematosus. J Rheumatol. 2004, 31: 1756-1762.PubMed

108.

Thomas MC, Cooper ME: Diabetes: bardoxolone improves kidney function in type 2 diabetes. Nat Rev. 2011, 7: 552-553.

109.

Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, Qian XX, Hirankarn N, Ying D, Pan HF, Mok CC, Chan TM, Wong RW, Lee KW, Mok MY, Wong SN, Leung AM, Li XP, Avihingsanon Y, Wong CM, Lee TL, Ho MH, Lee PP, Chang YK, Li PH, Li RJ, Zhang L, Wong WH, Ng IO, Lau CS, Sham PC, et al: Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet. 2010, 6: e1000841-10.1371/journal.pgen.1000841.PubMedCentralPubMed

110.

Dussaule JC, Guerrot D, Huby AC, Chadjichristos C, Shweke N, Boffa JJ, Chatziantoniou C: The role of cell plasticity in progression and reversal of renal fibrosis. Int J Exp Pathol. 2011, 92: 151-157. 10.1111/j.1365-2613.2011.00760.x.PubMedCentralPubMed

Title: Mechanisms of tissue injury in lupus nephritis
Authors: Tamara K Nowling
Gary S Gilkeson
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 6/2011
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar3528

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Application of in vivo micro-computed tomography in the temporal characterisation of subchondral bone architecture in a rat model of low-dose monosodium iodoacetate-induced osteoarthritis

Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan

Mutations in genes encoding complement inhibitors CD46 and CFHaffect the age at nephritis onset in patients with systemic lupus erythematosus

Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement

A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release

Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage